Asset Details
Do you wish to reserve the book?
Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia
Do you wish to request the book?
Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Fgfr3 enhancer deletion markedly improves all skeletal features in a mouse model of achondroplasia
2025
Overview
Achondroplasia, the most prevalent short-stature disorder, is caused by missense variants overactivating the fibroblast growth factor receptor 3 (FGFR3). As current surgical and pharmaceutical treatments only partially improve some disease features, we sought to explore a genetic approach. We show that an enhancer located 29 kb upstream of mouse Fgfr3 ( –29E ) is sufficient to confer a transgenic mouse reporter with a domain of expression in cartilage matching that of Fgfr3 . Its CRISPR/Cas9-mediated deletion in otherwise WT mice reduced Fgfr3 expression in this domain by half without causing adverse phenotypes. Importantly, its deletion in mice harboring the ortholog of the most common human achondroplasia variant largely normalized long bone and vertebral body growth, markedly reduced spinal canal and foramen magnum stenosis, and improved craniofacial defects. Consequently, mouse achondroplasia is no longer lethal, and adults are overall healthy. These findings, together with high conservation of –29E in humans, open a path to develop genetic therapies for people with achondroplasia.
Publisher
American Society for Clinical Investigation
Subject
/ Animals
/ CRISPR
/ Fibroblast growth factor receptor 3
/ Fibroblast growth factor receptors
/ Genetics
/ Humans
/ Kinases
/ Mice
/ Neomycin
/ Plasmids
/ Receptor, Fibroblast Growth Factor, Type 3 - biosynthesis
/ Receptor, Fibroblast Growth Factor, Type 3 - genetics
